15-days duration of venetoclax combined with azacitidine in the treatment of relapsed/refractory high-risk myelodysplastic syndromes: A retrospective single-center study.

导出原文传递

翻译打印收藏纠错

第一作者： Chen,Mei

第一单位： Myelodysplastic Syndromes Diagnosis and Therapy Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.

作者： Chen,Mei ^[1] ; Li,Ye ^[2] ; Yanling,Ren ^[3] ; Xinping,Zhou ^[1] ; Liya,Ma ^[2] ; Gaixiang,Xu ^[3] ; Weilai,Xu ^[1] ; Chenxi,Lu ^[2] ; Haiyang,Yang ^[3] ; Yingwan,Luo ^[1] ; Lingxu,Jiang ^[2] ; Wei,Lang ^[3] ; HongHu,Zhu ^[1] ; Jie,Jin ^[2] ; Hongyan,Tong ^[3]

作者单位： Myelodysplastic Syndromes Diagnosis and Therapy Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. ^[1] Department of Hematology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. ^[2] Zhejiang Province Key Laboratory of Hematology Oncology Diagnosis and Treatment, Hangzhou, Zhejiang, China. ^[3] Department of Hematology, Zhejiang Province People's Hospital, Hangzhou, China. ^[4] Cancer Center, Zhejiang University, Hangzhou, Zhejiang, China. ^[5]

关键词 MDS azacitidine relapsed/refractory venetoclax

主题词人类(Humans);阿扎胞苷(Azacitidine);回顾性研究(Retrospective Studies);骨髓增生异常综合征(Myelodysplastic Syndromes);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);白血病, 髓样, 急性(Leukemia, Myeloid, Acute)

DOI 10.1002/hon.3112

PMID 36516239

发布时间 2023-08-11

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交